Evidence map›Paper›PMID 41190023›Full record

ArticleFrontiers in pharmacology2025

Zhuriheng pills improve adipose tissue dysfunction and inflammation by modulating PPARγ to stabilize atherosclerotic plaques.

Qiong Zhai, Fangyuan Liang, Guanlin Yang, Zhimin Liu, Xin Dong, Ren Bu, Peifeng Xue, Shengsang Na, Xuan Zhang, Pengwei Zhao and 4 more

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. 3,3'-Di-O-methylellagic Acid Isolated fromPharmaceuticals (Basel, Switzerland) · 2026
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Qiong Zhai *School of Basic Medicine, Inner Mongolia Medical University, Huhehot, China.
Fangyuan Liang *School of Pharmaceutical and Environmental Engineering, Nantong Vocational University, Nantong, China.
Guanlin Yang *Pharmaceutical Department, Zaozhuang Thoracic hospital (Zaozhuang Cancer Hospital), Zaozhuang, China.
Zhimin LiuPharmaceutical Department, Chifeng College Affiliated Hospital, Chifeng, China.
Xin DongSchool of Pharmacy, Inner Mongolia Medical University, Huhehot, China.
Ren BuSchool of Pharmacy, Inner Mongolia Medical University, Huhehot, China.
Peifeng XueSchool of Pharmacy, Inner Mongolia Medical University, Huhehot, China.
Shengsang NaMedical Innovation Center for Nationalities, Inner Mongolia Medical University, Huhehot, China.
Xuan ZhangSchool of Basic Medicine, Inner Mongolia Medical University, Huhehot, China.
Pengwei ZhaoSchool of Basic Medicine, Inner Mongolia Medical University, Huhehot, China.
Xiaoning WangSchool of Basic Medicine, Inner Mongolia Medical University, Huhehot, China.
Qiang WeiSchool of Basic Medicine, Inner Mongolia Medical University, Huhehot, China.
Jingkun LuSchool of Basic Medicine, Inner Mongolia Medical University, Huhehot, China.
Yuewu WangSchool of Pharmacy, Inner Mongolia Medical University, Huhehot, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Adipose tissue dysfunction and chronic inflammation contribute to atherosclerosis plaque development. Zhuriheng pills (ZRH) are an effective Mongolian herbal formula used in treating coronary heart disease in China, but their mechanisms of action have not been fully elucidated. Purpose: To assess whether ZRH alleviates atherosclerosis (AS) and stabilizes plaque, this study investigates the modulatory effects of ZRH on AS and adipose tissue profiles in atherosclerotic model mice with vulnerable plaque to reveal the potential mechanisms and representative quality markers (Q-markers) of ZRH. Methods: Results: Conclusion: Our results demonstrated that ZRH stabilizes atherosclerotic plaques by ameliorating adipose tissue dysfunction and inflammation by regulating the PPARγ pathway.

Indexed as

Atherosclerotic plaquesPPARγ signaling pathwaythe adipose tissue dysfunctionthe adipose tissue dysfunction and inflammationthe adipose tissue inflammationZhuriheng Pills

Identifiers

PMID41190023
PMCPMC12580357

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.